Go to home

INTERCEPT

INTERCEPT...

Description

At INTERCEPT, we are transforming the landscape of Crohn’s disease research by shifting from reactive symptom management to proactive early detection and prevention. Our groundbreaking approach leverages biomarkers - measurable substances found in bo...

General Design

Type
Catalogue, Network
Start/End data collection
2025 (ongoing)

Population

Countries
United States of America (the), United Kingdom of Great Britain and Northern Ireland (the), Switzerland, Sweden, Spain, Portugal, Poland, Norway, Netherlands (the), Korea (the Republic of), Italy, Germany, France, Denmark, Belgium, Austria

Organisations

Lead organisations
Additional organisations
  • European Federation of Crohn's and Ulcerative Colitis Associations

    Other

  • United European Gastroenterology (UEG)

    Other

  • Aalborg Universitet

    Researcher

  • Centre Hospitalier Universitaire de Lille
    France
    https://www.chu-lille.fr

    Data originator

  • European Research and Project Office

    Other

  • Agostino Gemelli University Polyclinic
    Italy
    https://www.policlinicogemelli.it/

    Data originator

  • Gemelli Digital Medicine & Health

    Researcher

  • Vrije Universiteit Amsterdam (VU)
    Netherlands (the)
    https://vu.nl/

    Other

  • Richard Vesely

    Other

  • University Medical Center Groningen (UMCG)
    Netherlands (the)
    https://www.umcg.nl

    Data holder, Data provider, Researcher, Data access provider, Other

  • Norwegian University of Science and Technology

    Researcher

  • National Medical Institute of the Ministry of the Interior and Administration

    Data originator, Researcher

  • GLSMED Learning Health SA/Hospital da Luz

    Data provider

  • Örebro University

    Researcher

  • Celltrion Inc

    Other

  • Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU)

    Other

  • Takeda (Japan)
    Japan
    http://www.takeda.com

    Other

  • The Chancellor, Masters and Scholars of the University of Oxford

    Researcher

  • Ludger Limited

    Researcher

  • Icahn School of Medicine at Mount Sinai

    Researcher

  • Prometheus Laboratories Inc

    Other

Funding & Acknowledgements

Funding
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194780. The JU receives support from the European Union’s Horizon Europe Research and Innovation Programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, and Ludger Ltd, Celltrion Inc. and Prometheus Laboratories Inc. Co-Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Created with MOLGENIS